<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733889</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-06-02</org_study_id>
    <secondary_id>EudraCT number:2006-001880-42</secondary_id>
    <nct_id>NCT00733889</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma</brief_title>
  <official_title>Phase II, Multicentre, Uncontrolled Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Chemotherapy (Docetaxel, Cisplatin, 5-fluorouracil) as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy (Cisplatin) Plus Cetuximab in Patients With a Locoregional Esophageal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine efficacy ans safety of the combination of cetuximab&#xD;
      and chemotherapy (docetaxel, cisplatin, 5-fluorouracil) as neoadjuvant therapy followed&#xD;
      concomitant chemoradiotherapy (cisplatin) plus cetuximab in patients with a locoregional&#xD;
      esophageal carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Complete clinical response rate and objective clinical response rate after the administration of 3 cycles of chemotherapy plus cetuximab and after induction chemotherapy followed by concomitant chemoradiotherapy plus cetuximab</measure>
    <time_frame>2006-2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• To determine the complete pathological response rate in the patients subject to radical surgery, according to the investigators' criteria and the policy of each centre.</measure>
    <time_frame>2006-2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2006-2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To study the locoregional control of the disease, the therapeutic failure patterns, specific disease-free survival, event-free survival, disease-specific survival and global survival</measure>
    <time_frame>2006-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To determine EGFR expression in the tumour and attempt to correlate it with efficacy</measure>
    <time_frame>2006-2010</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Esophageal Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)</intervention_name>
    <description>Neoadjuvant chemotherapy plus cetuximab:&#xD;
3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.&#xD;
Radio-chemotherapy plus cetuximab:&#xD;
The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).&#xD;
Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent form signed before performing any of the study's specific procedures.&#xD;
&#xD;
          -  Age &gt; 18 and &lt; 70.&#xD;
&#xD;
          -  Karnofsky performance status &gt; 70% upon inclusion in the study.&#xD;
&#xD;
          -  Life expectancy of more than 3 months.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of squamous cell carcinoma or adenocarcinoma of the&#xD;
             oesophagus or the gastroesophageal junction. The disease must be confined to the&#xD;
             oesophagus or gastroesophageal junction and the perioesophageal region. There must be&#xD;
             no tumor extension beyond 2 cm into the stomach.&#xD;
&#xD;
          -  Stages II or III. The patients must have a T1N1M0 or T2-4; any N; M0. The only&#xD;
             exception would be patients with stage IVA: an oesophageal carcinoma of the upper&#xD;
             thoracic region with metastasis in cervical lymph nodes (M1a) and an oesophageal&#xD;
             carcinoma of the lower thoracic region with metastasis in the celiac lymph nodes&#xD;
             (M1a), providing the disease remains within the radiotherapy fields.&#xD;
&#xD;
          -  Presence of a unidimensionally measurable and/or assessable lesion&#xD;
&#xD;
          -  Neutrophils &gt;1500/mm3, platelet count &gt;150,000/mm3 and haemoglobin &gt;10 g/dl.&#xD;
&#xD;
          -  Adequate renal function: serum creatinine &lt; 120 micromol/l (1.4 mg/dl); if the values&#xD;
             are &gt;120 micromol/l (1.4 mg/dl) creatinine clearance must be &gt; 65 ml/min.&#xD;
&#xD;
          -  Adequate liver function: total bilirubin &lt;1 x NUL; aspartate aminotransferase (AST)&#xD;
             and alanine aminotransferase (ALT) &lt;2.5 x NUL; alkaline phosphatase (AP) &lt; 5 x NUL.&#xD;
             Patients with AST and/or ALT &gt; 1.5 &lt; 2.5 x NUL and AP &gt; 1.5 x NUL &lt; 5 x NUL are not&#xD;
             eligible.&#xD;
&#xD;
          -  Serum calcium &lt;1.25 x normal upper limit (NUL).&#xD;
&#xD;
          -  Adequate nutritional status: weight loss &lt; 20% of regular weight and albumin &gt; 35 g/l.&#xD;
&#xD;
          -  Total oral and/or enteral intake should be at least 1700 calories/day.&#xD;
&#xD;
          -  Use of an effective contraceptive method for patients of both sexes when there is a&#xD;
             risk of conception and/or pregnancy.&#xD;
&#xD;
          -  Availability of tumour tissue for immunohistochemical analysis of EGFR expression and&#xD;
             other biological markers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a tracheo-oesophageal fistula or direct invasion of the tracheal mucosa&#xD;
             or a major bronchi are not eligible. Bronchoscopy (with biopsy and cytology if lesion&#xD;
             is seen) is required in order to rule out a fistula and/or direct invasion if the&#xD;
             primary tumour is &lt; than 30 cm from the incisors. Bronchoscopy is also required when&#xD;
             the primary tumour is shown to be at or above the carina by an imaging study.&#xD;
&#xD;
          -  Prior thoracic radiotherapy and/or systemic chemotherapy and/or oesophageal surgery.&#xD;
&#xD;
          -  Patients with multiple carcinoma of the oesophagus.&#xD;
&#xD;
          -  Diagnosis of any other cancer in the previous 5 years with the exception of&#xD;
             appropriately treated carcinoma in situ of the uterine cervix and/or basal cell&#xD;
             carcinoma of the skin.&#xD;
&#xD;
          -  Systemic, chronic and concomitant immune treatment, or anti-cancer hormone therapy.&#xD;
&#xD;
          -  Other concomitant cancer treatments.&#xD;
&#xD;
          -  Active infection (infection requiring intravenous antibiotics), including active&#xD;
             tuberculosis and diagnosed HIV.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 180 mmHg and/or&#xD;
             diastolic blood pressure &gt; 130 mmHg at rest.&#xD;
&#xD;
          -  Active, uncontrolled, gastric or duodenal peptic ulcer.&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease requiring hospitalisation in the 6 months prior&#xD;
             to inclusion in the study.&#xD;
&#xD;
          -  History of atrioventricular arrhythmia and/or cardiac failure and/or second or third&#xD;
             degree heart block.&#xD;
&#xD;
          -  Clinically significant coronary artery disease or history of myocardial infarction in&#xD;
             the last 12 months .&#xD;
&#xD;
          -  Peripheral neuropathy grade &gt; 2 NCIC-CTG of any aetiology.&#xD;
&#xD;
          -  Hearing disorder grade &gt; 2 NCIC-CTG of any aetiology.&#xD;
&#xD;
          -  Any other disease or medical disorder suggesting that the patient will not be able to&#xD;
             complete the study.&#xD;
&#xD;
          -  Any psychological disorder suggesting that the complete treatment will not be&#xD;
             possible.&#xD;
&#xD;
          -  Pregnancy (its absence must be confirmed by the serum HCG-betatest) or lactation.&#xD;
&#xD;
          -  Known drug abuse (with the exception of the mild or moderate consumption of alcohol&#xD;
             upon inclusion in the study).&#xD;
&#xD;
          -  Known allergic reaction to any of the components in the study treatment.&#xD;
&#xD;
          -  Prior treatment with monoclonal antibodies or other signal transduction inhibitors or&#xD;
             EGFR-targeted treatment.&#xD;
&#xD;
          -  Evidence of another cancer, with the exception of a carcinoma in situ of the uterine&#xD;
             cervix and/or a basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Any experimental treatment in the 30 days prior to inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Tabernero, MD; phD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Oncology Department; Hospital Universitario Vall d'Hebrón; Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jordi Giralt, MD; phD</last_name>
    <role>Study Chair</role>
    <affiliation>Oncology Radiation Department; Hospital Universitario Vall d'Hebrón; Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal carcinoma</keyword>
  <keyword>cetuximab</keyword>
  <keyword>docetaxel</keyword>
  <keyword>cisplatin</keyword>
  <keyword>5-fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

